C12N 2740/16051
Methods of production or purification of viral material
C12N2740/16051 (Methods of production or purification of viral material) appears on 248 US grants and 400 published applications in this corpus.
Search patents in C12N- Granted patents
- 248
- Published applications
- 400
- Assignees
- 222
- Inventors
- 756
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 2 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 5 | 0 |
| 1999 | 6 | 0 |
| 2000 | 6 | 0 |
| 2001 | 12 | 1 |
| 2002 | 6 | 10 |
| 2003 | 12 | 20 |
| 2004 | 11 | 8 |
| 2005 | 5 | 9 |
| 2006 | 4 | 5 |
| 2007 | 10 | 6 |
| 2008 | 2 | 10 |
| 2009 | 2 | 8 |
| 2010 | 6 | 8 |
| 2011 | 4 | 9 |
| 2012 | 7 | 11 |
| 2013 | 2 | 9 |
| 2014 | 4 | 8 |
| 2015 | 4 | 13 |
| 2016 | 6 | 17 |
| 2017 | 13 | 15 |
| 2018 | 12 | 20 |
| 2019 | 13 | 23 |
| 2020 | 9 | 24 |
| 2021 | 13 | 29 |
| 2022 | 9 | 28 |
| 2023 | 15 | 21 |
| 2024 | 13 | 39 |
| 2025 | 19 | 33 |
| 2026 | 6 | 16 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Compositions for transfecting a nucleic acid molecule into a cell comprising benzo-fused heterocyclic compounds grafted to a cationic polymer, and their applications25 Aug 2026US 12,716,075 B2Sartorius Polyplus
- Polynucleotide for physiological expression in T-cells19 May 2026US 12,630,843 B2FundacióN PúBlica Andaluza Progreso Y Salud
- Expression of products from nucleic acid concatemers7 Apr 2026US 12,595,501 B2Global Life Sciences Solutions USA LLC
- Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof31 Mar 2026US 12,590,321 B2Exuma Biotech Corp.
- Method for large-scale preparation of purified preparation of recombinant lentiviral vector at GMP grade17 Mar 2026US 12,577,541 B2Abelzeta Inc.
- Methods of producing hiv-1 envelope glycoproteins and guanosine microparticles thereof24 Sep 2026US 2026/0285913 A1
- Dual targeted gene therapy17 Sep 2026US 2026/0275377 A1Kelonia Therapeutics, Inc.
- Methods and kits for the improved fermentative production of a recombinant virus20 Aug 2026US 2026/0242822 A1Takeda Pharmaceutical Company Limited
- Pseudotyped viral particles for targeting tcr-expressing cells6 Aug 2026US 2026/0226500 A1Regeneron Pharmaceuticals, Inc.
- Purification of viruses, virus-like particles, and globular biomolecules by filtration-supported polyalkylene glycol precipitation30 Jul 2026US 2026/0216667 A1
Most cited
By later US patents
- Method and means for producing high titer, safe, recombinant lentivirus vectors261US 5,994,136 ACell Genesys, Inc. · 1999
- Human immunodeficiency viruses associated with Acquired Immune Deficiency Syndrome (AIDS), a diagnostic method for AIDS and pre-AIDS, and a kit therefor144US 4,708,818 AInstitut Pasteur · 1987
- Lentivirus vector system92US 6,790,657 B1The United States of America as represented by the Department of Health and Human Services · 2004
- Method and means for producing high titer, safe, recombinant lentivirus vectors89US 6,165,782 ACell Genesys, Inc. · 2000
- Expression of HIV polypeptides and production of virus-like particles73US 6,602,705 B1Chiron Corporation · 2003